02532nam 2200397 450 991068814920332120230625160015.010.5772/intechopen.95137(CKB)5580000000514504(NjHacI)995580000000514504(EXLCZ)99558000000051450420230625d2022 uy 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierMesothelioma diagnostics, treatment and basic research /Ilze Strumfa, Romans Uljanovs, Boriss Strumfs, editorsLondon :IntechOpen,2022.1 online resource (142 pages)1-80355-350-2 Includes bibliographical references.1. Causes and Pathogenesis of Malignant Mesothelioma -- 2. Epigenomics in Malignant Pleural Mesothelioma -- 3. Mesothelioma: Overview of Technical, Immunochemical and Pathomorphological Diagnosing Aspects -- 4. Fibulin-3 as a Biomarker of Pleuric Involvement by Exposure to Fibers -- 5. Surgical Management of Malignant Pleural Mesothelioma: From the Past to the Future -- 6. Recent Advances in Systemic Therapy for Malignant Pleural Mesothelioma: Focus on Anti-Angiogenic Inhibitors and Immune Checkpoint Inhibitors.This book is devoted to the state of the art, pitfalls and perspectives in the diagnosis and treatment of mesothelioma - a peculiar malignant tumour arising from mesothelial cells that line the pleura, the pericardium and the peritoneum. Mesothelioma is known for its strong association with asbestos exposure, difficult surgical treatment and dismal prognosis. However, recent years have yielded significant discoveries on, for example, germline mutations in BAP1 gene coding BRCA1-associated protein 1, the pathogenetic role of inflammation, and innovative treatment approaches such as immune checkpoint inhibitors. The volume is intended to summarise classic views and innovations in the pathogenetic concepts, diagnostics, treatment and scientific studies of mesothelioma, resulting in a comprehensive reference work as well as a source of ideas for relevant clinical and basic research.MesotheliomaMesothelioma.616.99424Strumfs BorissUljanovs RomansStrumfa IlzeNjHacINjHaclBOOK9910688149203321Mesothelioma1737428UNINA